دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
New challenges for interventional cardiology emerging in trials and real-world studies
Filippo Crea
doi : 10.1093/eurheartj/ehab448
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2615–2619
New medical tools advance cardiac interventions
Mark Nicholls
doi : 10.1093/eurheartj/ehab338
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2620–2622
Heroes, politics and media: the unshakable medical practice in the pandemic
Dimitrios A Vrachatis, Spyridon G Deftereos, Alexandra Lansky
doi : 10.1093/eurheartj/ehab101
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2622–2625
Digital, risk-based screening for atrial fibrillation in the European community—the AFFECT-EU project funded by the European Union
Daniel Engler, Hein Heidbuchel, Renate B Schnabel, for the AFFECT-EU Investigators
doi : 10.1093/eurheartj/ehab050
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2625–2627
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonism and Exercise: An Effective Strategy to Maintain Diet-Induced Weight Loss
Leonarda Galiuto, Giovanna Liuzzo
doi : 10.1093/eurheartj/ehab356
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2628–2629
Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Heerajnarain Bulluck, Valeria Paradies, Emanuele Barbato, Andreas Baumbach, Hans Erik B?tker, Davide Capodanno, Raffaele De Caterina, Claudio Cavallini, Sean M Davidson, Dmitriy N Feldman, Péter Ferdinandy, Sebastiano Gili, Mariann Gy?ngy?si, Vijay Kunadian, Sze-Yuan Ooi, Rosalinda Madonna, Michael Marber, Roxana Mehran, Gjin Ndrepepa, Cinzia Perrino, Stefanie Schüpke, Johanne Silvain, Joost P G Sluijter, Giuseppe Tarantini, Gabor G Toth, Linda W Van Laake, Clemens von Birgelen, Michel Zeitouni, Allan S Jaffe, Kristian Thygesen, Derek J Hausenloy
doi : 10.1093/eurheartj/ehab271
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2630–2642
A substantial number of chronic coronary syndrome (CCS) patients undergoing percutaneous coronary intervention (PCI) experience periprocedural myocardial injury or infarction. Accurate diagnosis of these PCI-related complications is required to guide further management given that their occurrence may be associated with increased risk of major adverse cardiac events (MACE). Due to lack of scientific data, the cut-off thresholds of post-PCI cardiac troponin (cTn) elevation used for defining periprocedural myocardial injury and infarction, have been selected based on expert consensus opinions, and their prognostic relevance remains unclear. In this Consensus Document from the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI), we recommend, whenever possible, the measurement of baseline (pre-PCI) cTn and post-PCI cTn values in all CCS patients undergoing PCI. We confirm the prognostic relevance of the post-PCI cTn elevation >5× 99th percentile URL threshold used to define type 4a myocardial infarction (MI). In the absence of periprocedural angiographic flow-limiting complications or electrocardiogram (ECG) and imaging evidence of new myocardial ischaemia, we propose the same post-PCI cTn cut-off threshold (>5× 99th percentile URL) be used to define prognostically relevant ‘major’ periprocedural myocardial injury. As both type 4a MI and major periprocedural myocardial injury are strong independent predictors of all-cause mortality at 1 year post-PCI, they may be used as quality metrics and surrogate endpoints for clinical trials. Further research is needed to evaluate treatment strategies for reducing the risk of major periprocedural myocardial injury, type 4a MI, and MACE in CCS patients undergoing PCI.
Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials
Mahesh V Madhavan, James P Howard, Azim Naqvi, Ori Ben-Yehuda, Bjorn Redfors, Megha Prasad, Bahira Shahim, Martin B Leon, Sripal Bangalore, Gregg W Stone, Yousif Ahmad
doi : 10.1093/eurheartj/ehab280
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2643–2654
Contemporary 2nd-generation thin-strut drug-eluting stents (DES) are considered standard of care for revascularization of patients undergoing percutaneous coronary intervention. A previous meta-analysis of 10 randomized controlled trials (RCTs) with 11 658 patients demonstrated a 16% reduction in the 1-year risk of target lesion failure (TLF) with ultrathin-strut DES compared with conventional 2nd-generation thin-strut DES. Whether this benefit is sustained longer term is not known, and newer trial data may inform these relative outcomes. We therefore sought to perform an updated systematic review and meta-analysis of RCTs comparing clinical outcomes with ultrathin-strut DES (?70?µm strut thickness) with conventional 2nd-generation thin-strut DES.
Meta-analyses of moving targets
Colin Berry
doi : 10.1093/eurheartj/ehab359
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2655–2656
Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Sebastian V?lz, Bj?rn Redfors, Oskar Anger?s, Dan Ioanes, Jacob Odenstedt, Sasha Koul, Inger Valeljung, Christian Dworeck, Robin Hofmann, Emma Hansson, Dimitrios Venetsanos, Anders Ulvenstam, Tomas Jernberg, Truls R?munddal, Pétur Pétursson, Ole Fr?bert, David Erlinge, Anders Jeppsson, Elmir Omerovic
doi : 10.1093/eurheartj/ehab273
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2657–2664
To compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for treatment of patients with heart failure due to ischaemic heart disease.
Coronary artery bypass grafting versus percutaneous coronary intervention in ischaemic heart failure. Can reliable treatment decisions in high-risk patients be based on non-randomized data?
Masafumi Ono, Scot Garg, Yoshinobu Onuma, Patrick W Serruys
doi : 10.1093/eurheartj/ehab349
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2665–2669
A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial
Alexandra J Lansky, Rajendra Makkar, Tamim Nazif, Steven Messé, John Forrest, Rahul Sharma, Joachim Schofer, Axel Linke, David Brown, Abhijeet Dhoble, Phillip Horwitz, Ming Zang, Frederico DeMarco, Vivek Rajagopal, Michael G Dwyer, Robert Zivadinov, Pieter Stella, Joshua Rovin, Helen Parise, Susheel Kodali, Andreas Baumbach, Jeffrey Moses the REFLECT I Trial Investigators
doi : 10.1093/eurheartj/ehab213
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2670–2679
The REFLECT I trial investigated the safety and effectiveness of the TriGuard™ HDH (TG) cerebral embolic deflection device in patients undergoing transcatheter aortic valve replacement (TAVR).
Reflective learning on the role of cerebral embolic protection in TAVI patients?
Rajesh K Kharbanda
doi : 10.1093/eurheartj/ehab212
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2680–2682
Impact of sex on the management and outcome of aortic stenosis patients
David Bienjonetti-Boudreau, Marie-Ange Fleury, Martine Voisine, Amélie Paquin, Isabelle Chouinard, Mathieu Tailleur, Raphael Duval, Pierre-Olivier Magnan, Jonathan Beaudoin, Erwan Salaun, Marie-Annick Clavel
doi : 10.1093/eurheartj/ehab242
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2683–2691
The aim of this study was to assess the impact of sex on the management and outcome of patients according to aortic stenosis (AS) severity.
Impact of sex on the management and outcome of aortic stenosis patients: a female aortic valve stenosis paradox, and a call for personalized treatments?
Georg Goliasch, Irene M Lang
doi : 10.1093/eurheartj/ehab331
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2692–2694
Immediate post-procedural functional assessment of percutaneous coronary intervention: current evidence and future directions
Daixin Ding, Jiayue Huang, Jelmer Westra, David Joel Cohen, Yundai Chen, Birgitte Krogsgaard Andersen, Niels Ramsing Holm, Bo Xu, Shengxian Tu, William Wijns
doi : 10.1093/eurheartj/ehab186
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2695–2707
Percutaneous coronary intervention (PCI) guided by coronary physiology provides symptomatic benefit and improves patient outcomes. Nevertheless, over one-fourth of patients still experience recurrent angina or major adverse cardiac events following the index procedure. Coronary angiography, the current workhorse for evaluating PCI efficacy, has limited ability to identify suboptimal PCI results. Accumulating evidence supports the usefulness of immediate post-procedural functional assessment. This review discusses the incidence and possible mechanisms behind a suboptimal physiology immediately after PCI. Furthermore, we summarize the current evidence base supporting the usefulness of immediate post-PCI functional assessment for evaluating PCI effectiveness, guiding PCI optimization, and predicting clinical outcomes. Multiple observational studies and post hoc analyses of datasets from randomized trials demonstrated that higher post-PCI functional results are associated with better clinical outcomes as well as a reduced rate of residual angina and repeat revascularization. As such, post-PCI functional assessment is anticipated to impact patient management, secondary prevention, and resource utilization. Pre-PCI physiological guidance has been shown to improve clinical outcomes and reduce health care costs. Whether similar benefits can be achieved using post-PCI physiological assessment requires evaluation in randomized clinical outcome trials.
Ticagrelor monotherapy following percutaneous coronary intervention for acute coronary syndrome in TWILIGHT patients: still a future for aspirin?
Mattia Lunardi, Yoshinobu Onuma, Patrick W Serruys
doi : 10.1093/eurheartj/ehab037
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2708–2709
Aspirin-free strategies: a framework to reassess the role of dual antiplatelet therapy after percutaneous coronary intervention
Davide Cao, Usman Baber, Roxana Mehran
doi : 10.1093/eurheartj/ehab041
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2710–2711
Emergent endovascular repair of a huge aortic arch aneurysm with aortopulmonary fistula secondary to Takayasu’s arteritis
Buqing Ni, Jiaxi Gu, Minghui Li, Yongfeng Shao
doi : 10.1093/eurheartj/ehab022
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Page 2712
‘Small bifurcation?’ CT myocardial mass volume measurements change therapeutic strategy in coronary artery disease
Youssef S Abdelwahed, Anne-Sophie Schatz, Ulf Landmesser, Carsten Skurk
doi : 10.1093/eurheartj/ehaa990
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Pages 2713–2714
Erratum to: Alcohol Consumption, Cardiac Biomarkers and Risk of Atrial Fibrillation and Adverse Outcomes
doi : 10.1093/eurheartj/ehab344
European Heart Journal, Volume 42, Issue 27, 14 July 2021, Page 2711
